- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 24 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.3: 6 residues within 4Å:- Chain A: E.54, V.56, N.208, N.220, S.222
- Ligands: NAG.39
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:E.54, A:V.56
NAG-NAG-BMA.11: 7 residues within 4Å:- Chain A: N.310, E.384, G.385, N.386
- Ligands: NAG-NAG.10, NAG-NAG.12, NAG-NAG.12
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.15: 6 residues within 4Å:- Chain E: E.54, V.56, N.208, N.220, S.222
- Ligands: NAG.54
2 PLIP interactions:2 interactions with chain E- Hydrophobic interactions: E:E.54, E:V.56
NAG-NAG-BMA.23: 7 residues within 4Å:- Chain E: N.310, E.384, G.385, N.386
- Ligands: NAG-NAG.22, NAG-NAG.24, NAG-NAG.24
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.27: 6 residues within 4Å:- Chain G: E.54, V.56, N.208, N.220, S.222
- Ligands: NAG.69
2 PLIP interactions:2 interactions with chain G- Hydrophobic interactions: G:E.54, G:V.56
NAG-NAG-BMA.35: 7 residues within 4Å:- Chain G: N.310, E.384, G.385, N.386
- Ligands: NAG-NAG.34, NAG-NAG.36, NAG-NAG.36
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.4: 13 residues within 4Å:- Chain A: R.37, P.185, P.191, V.233, L.240, N.241, R.283, N.354, G.356, C.418, S.419, S.420
- Ligands: NAG-NAG.6
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:S.419
NAG-NAG-BMA-MAN-MAN-MAN.16: 13 residues within 4Å:- Chain E: R.37, P.185, P.191, V.233, L.240, N.241, R.283, N.354, G.356, C.418, S.419, S.420
- Ligands: NAG-NAG.18
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:S.419
NAG-NAG-BMA-MAN-MAN-MAN.28: 13 residues within 4Å:- Chain G: R.37, P.185, P.191, V.233, L.240, N.241, R.283, N.354, G.356, C.418, S.419, S.420
- Ligands: NAG-NAG.30
1 PLIP interactions:1 interactions with chain G- Hydrogen bonds: G:S.419
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.5: 7 residues within 4Å:- Chain A: N.255
- Chain C: G.107, Q.108, G.109
- Chain D: G.29, H.30, G.66
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.17: 7 residues within 4Å:- Chain E: N.255
- Chain I: G.107, Q.108, G.109
- Chain J: G.29, H.30, G.66
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.29: 7 residues within 4Å:- Chain G: N.255
- Chain K: G.107, Q.108, G.109
- Chain L: G.29, H.30, G.66
No protein-ligand interaction detected (PLIP)- 45 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.37: 4 residues within 4Å:- Chain A: I.163, R.171, N.176
- Chain G: V.144
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain A: A.58, N.59
- Chain B: G.17, S.18
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain A: N.209, N.220
- Ligands: NAG-NAG.2, NAG-NAG-BMA.3
Ligand excluded by PLIPNAG.40: 4 residues within 4Å:- Chain A: L.105, G.302, N.303, I.304
Ligand excluded by PLIPNAG.41: 1 residues within 4Å:- Chain A: N.333
Ligand excluded by PLIPNAG.42: 5 residues within 4Å:- Chain A: T.365, Q.366, N.369
- Ligands: NAG-NAG.8, NAG-NAG.8
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain A: N.280, I.301, Q.415
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain A: Y.373, G.374, N.375
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain A: E.247, E.248, N.268, E.269
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain A: N.165, D.166, N.167
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain A: N.139, M.148
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain A: N.435
- Chain D: E.1, I.2
Ligand excluded by PLIPNAG.49: 3 residues within 4Å:- Chain B: N.101, S.103, W.104
Ligand excluded by PLIPNAG.50: 4 residues within 4Å:- Chain B: K.123, E.124, S.126, N.127
Ligand excluded by PLIPNAG.51: 2 residues within 4Å:- Chain B: N.111, N.115
Ligand excluded by PLIPNAG.52: 4 residues within 4Å:- Chain A: V.144
- Chain E: I.163, R.171, N.176
Ligand excluded by PLIPNAG.53: 4 residues within 4Å:- Chain E: A.58, N.59
- Chain F: G.17, S.18
Ligand excluded by PLIPNAG.54: 4 residues within 4Å:- Chain E: N.209, N.220
- Ligands: NAG-NAG.14, NAG-NAG-BMA.15
Ligand excluded by PLIPNAG.55: 4 residues within 4Å:- Chain E: L.105, G.302, N.303, I.304
Ligand excluded by PLIPNAG.56: 1 residues within 4Å:- Chain E: N.333
Ligand excluded by PLIPNAG.57: 5 residues within 4Å:- Chain E: T.365, Q.366, N.369
- Ligands: NAG-NAG.20, NAG-NAG.20
Ligand excluded by PLIPNAG.58: 3 residues within 4Å:- Chain E: N.280, I.301, Q.415
Ligand excluded by PLIPNAG.59: 3 residues within 4Å:- Chain E: Y.373, G.374, N.375
Ligand excluded by PLIPNAG.60: 4 residues within 4Å:- Chain E: E.247, E.248, N.268, E.269
Ligand excluded by PLIPNAG.61: 3 residues within 4Å:- Chain E: N.165, D.166, N.167
Ligand excluded by PLIPNAG.62: 2 residues within 4Å:- Chain E: N.139, M.148
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain E: N.435
- Chain J: E.1, I.2
Ligand excluded by PLIPNAG.64: 3 residues within 4Å:- Chain F: N.101, S.103, W.104
Ligand excluded by PLIPNAG.65: 4 residues within 4Å:- Chain F: K.123, E.124, S.126, N.127
Ligand excluded by PLIPNAG.66: 2 residues within 4Å:- Chain F: N.111, N.115
Ligand excluded by PLIPNAG.67: 4 residues within 4Å:- Chain E: V.144
- Chain G: I.163, R.171, N.176
Ligand excluded by PLIPNAG.68: 4 residues within 4Å:- Chain G: A.58, N.59
- Chain H: G.17, S.18
Ligand excluded by PLIPNAG.69: 4 residues within 4Å:- Chain G: N.209, N.220
- Ligands: NAG-NAG.26, NAG-NAG-BMA.27
Ligand excluded by PLIPNAG.70: 4 residues within 4Å:- Chain G: L.105, G.302, N.303, I.304
Ligand excluded by PLIPNAG.71: 1 residues within 4Å:- Chain G: N.333
Ligand excluded by PLIPNAG.72: 5 residues within 4Å:- Chain G: T.365, Q.366, N.369
- Ligands: NAG-NAG.32, NAG-NAG.32
Ligand excluded by PLIPNAG.73: 3 residues within 4Å:- Chain G: N.280, I.301, Q.415
Ligand excluded by PLIPNAG.74: 3 residues within 4Å:- Chain G: Y.373, G.374, N.375
Ligand excluded by PLIPNAG.75: 4 residues within 4Å:- Chain G: E.247, E.248, N.268, E.269
Ligand excluded by PLIPNAG.76: 3 residues within 4Å:- Chain G: N.165, D.166, N.167
Ligand excluded by PLIPNAG.77: 2 residues within 4Å:- Chain G: N.139, M.148
Ligand excluded by PLIPNAG.78: 3 residues within 4Å:- Chain G: N.435
- Chain L: E.1, I.2
Ligand excluded by PLIPNAG.79: 3 residues within 4Å:- Chain H: N.101, S.103, W.104
Ligand excluded by PLIPNAG.80: 4 residues within 4Å:- Chain H: K.123, E.124, S.126, N.127
Ligand excluded by PLIPNAG.81: 2 residues within 4Å:- Chain H: N.111, N.115
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Schorcht, A. et al., The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. J.Virol. (2022)
- Release Date
- 2021-09-15
- Peptides
- AMC016 gp120: AEG
AMC016 gp41: BFH
PGV04 Fab heavy chain: CIK
PGV04 kappa chain: DJL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CG
DB
BF
EH
FC
HI
GK
ID
LJ
JL
K
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 24 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 45 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Schorcht, A. et al., The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. J.Virol. (2022)
- Release Date
- 2021-09-15
- Peptides
- AMC016 gp120: AEG
AMC016 gp41: BFH
PGV04 Fab heavy chain: CIK
PGV04 kappa chain: DJL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CG
DB
BF
EH
FC
HI
GK
ID
LJ
JL
K